| Literature DB >> 35603628 |
Farshid Dayyani1, Brian R Smith2, Ninh T Nguyen2, Shaun Daly2, Marcelo W Hinojosa2, Steven N Seyedin3, Jeffrey Kuo3, Jason B Samarasena1, John G Lee1, Thomas H Taylor4, May T Cho1, Maheswari Senthil2.
Abstract
Current guidelines recommend neoadjuvant (NAC) and/or adjuvant chemotherapy for locally advanced gastric cancers (LAGCs). However, the choice and duration of NAC regimen is standardized, rather than personalized to biologic response, despite the availability of several different classes of agents for the treatment of gastric cancer (GC). The current trial will use a tumor-informed ctDNA assay (Signatera™) and monitor response to NAC. Based on ctDNA kinetics, the treatment regimen is modified. This is a prospective single center, single-arm, open-label study in clinical stage IB-III GC. ctDNA is measured at baseline and repeated every 8 weeks. Imaging is performed at the same intervals. The primary end point is the feasibility of this approach, defined as percentage of patients completing gastrectomy.Entities:
Keywords: ctDNA; gastrectomy; gastric cancer; neoadjuvant chemotherapy
Mesh：
Year: 2022 PMID： 35603628 PMCID： PMC9437768 DOI： 10.2217/fon-2022-0285
Source DB: PubMed Journal: Future Oncol ISSN： 1479-6694 Impact factor: 3.674